September 25, 2023
The Japanese health ministry on September 25 granted approval for Leqembi (lecanemab), an Alzheimer’s disease (AD) treatment developed by Eisai and Biogen, making it the first AD-modifying therapy in Japan. Leqembi was approved for slowing the progression of mild cognitive...read more